Drug Type Trispecific T-cell engager (TriTE) |
Synonyms DR-30310 |
Target |
Action stimulants, inhibitors, agonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CLDN18.2 inhibitors(Claudin 18.2 inhibitors), albumin agonists(Serum albumin agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 31 Jul 2022 |






